Objective: There is widespread consensus that the EEG is not useful for the detection of clinically relevant abnormalities in patients with psychosis. Given that the EEG records brain dysfunction, this study examines whether an abnormal EEG in first-episode psychosis patients is associated with poorer prognosis, compared with a normal EEG.
Method: At their initial assessment, 61 patients with first-episode psychosis had an EEG classified according to the following modified Mayo Clinic system: normal, essentially normal (that is, one or more elements of questionable normality), or dysrhythmia (grade I to V). We assessed psychiatric symptoms using the Scale for Assessment of Negative Symptoms (SANS) and the Scale for Assessment of Positive Symptoms (SAPS) on entry and after 1 year of treatment. Psychosis is considered to have remitted if there are no, or minimal, psychotic symptoms (that is, a rating of 2 or less on every SAPS global rating), maintained for 1 month.
Results: At the end of 1 year, 19/21 (90.5%) patients with a normal EEG had a remission of their positive symptoms, compared with 18/28 (64.3%) of those with an essentially normal EEG and only 7/12 (58.3%) of those with dysrhythmia. Negative symptoms were reduced by more than 50% in 11/18 (61.1%) patients with a normal EEG, compared with 10/28 (35.7%) patients with an essentially normal EEG. None of the 8 patients with dysrhythmia on their EEG experienced reduced negative symptoms.
Conclusion: The above findings suggest that an abnormal EEG in patients with first-episode psychosis is associated with a poorer prognosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/070674370304801103 | DOI Listing |
Cell Rep Med
January 2025
DiMePRe-J-Department of Precision and Rigenerative Medicine-Jonic Area, University of Bari "Aldo Moro", Bari, Italy.
The diagnosis of autism is currently based on the developmental history, direct observation of behavior, and reported symptoms, supplemented by rating scales/interviews/structured observational evaluations-which is influenced by the clinician's knowledge and experience-with no established diagnostic biomarkers. A growing body of research has been conducted over the past decades to improve diagnostic accuracy. Here, we provide an overview of the current diagnostic assessment process as well as of recent and ongoing developments to support diagnosis in terms of genetic evaluation, telemedicine, digital technologies, use of machine learning/artificial intelligence, and research on candidate diagnostic biomarkers.
View Article and Find Full Text PDFEarly Interv Psychiatry
February 2025
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA.
Objective: Early intervention in psychosis is associated with favourable outcomes. We investigated whether loved ones' illness duration moderated caregiver outcomes following a Cognitive Behavioural Therapy-informed Family Intervention for psychosis (FIp).
Methods: We conducted a secondary analysis of measures of FIp participants' depression and anxiety symptoms, caregiver appraisals, expressed emotion and foundational psychotherapeutic competencies at pre-, post- and 4-month follow-up.
Psychoneuroendocrinology
January 2025
King's College London, Institute of Psychiatry, Psychology & Neuroscience, Department of Psychosis Studies, London, UK; National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK; Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Electronic address:
Background: Studies of salivary cortisol levels in psychosis have yielded inconsistent findings, which may be attributable to heterogeneity in cortisol measurement, illness stage, and approaches to dealing with sampling factors and potential confounders. To address these issues, we performed an individual participant data (IPD) meta-analysis comparing individuals at different stages of psychosis to controls using five different salivary cortisol measures and explored potential effect modifiers.
Methods: Salivary cortisol data from five London-based cohorts were used to derive the cortisol awakening response, total daytime cortisol output, basal cortisol, and diurnal slope measures (wake-to-evening and peak-to-evening).
HRB Open Res
January 2025
Department of Psychiatry, University College Dublin, Dublin, Leinster, Ireland.
Background: Individuals with first-episode psychosis (FEP) face an increased risk of physical comorbidities, notably cardiovascular diseases, metabolic disorders, respiratory disorders, and certain types of cancer. Previous reviews report pooled physical health prevalence from chronic psychosis and FEP groups. By contrast, this review will focus on antipsychotic-naïve FEP cohorts and incorporate data from observational longitudinal studies and antipsychotic intervention studies to understand the progression of physical health comorbidities from the onset to later stages of psychosis.
View Article and Find Full Text PDFEarly Interv Psychiatry
February 2025
Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA.
Background: Fostering positive relationships with mental health professionals and involving family in treatment can reduce untreated psychosis duration and prevent dropout.
Aims: The present study explores the experiences of young adults with psychosis as they engage in mental health treatment and communicate with family caregivers. Describing their lived experiences would inform the clinical engagement process and pathways to clinical outcomes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!